News und Analysen

Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g., more than 5%), usually there's a reason behind it. And investors are often hesitant to invest in

Space and defense stock Voyager Technologies (NYSE: VOYG) took off like a rocket packed with fuel on Monday. The company's shares gained more than 13% in value after it divulged an investment into

Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week.

The clinical-stage biotech

AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate

Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar

Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares

Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies.

That's

We're well into the home stretch of 2025. August is more than halfway over. But there's still plenty of time remaining in the year -- and in this month -- to invest in stocks that hold the potential

Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.

Investors looking for companies that fit

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the

ImmuCell(NASDAQ:ICCC) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million

Even well-established drugmakers can lose significant market value overnight following a setback. That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX). The company's shares fell by

We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and CoreWeave (NASDAQ: CRWV). To learn more, check out the short video, consider

Pfizer (NYSE: PFE) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID vaccine resulted in the business posting record sales and profits in 2022. But

TuHURA Biosciences (NASDAQ:HURA), a biotechnology company focused on immuno-oncology therapies, released its second quarter results on August 14, 2025. The big headlines included the start of a

ImmuCell (NASDAQ:ICCC), a specialist in animal health products for the dairy and beef industries, issued its earnings results for the second quarter of fiscal 2025 on August 14, 2025. The company

Tvardi Therapeutics (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on developing new therapies for serious diseases, released its second quarter fiscal 2025 results on August 14

Omeros (NASDAQ:OMER), a biopharmaceutical company focused on developing treatments for rare diseases and immune-related conditions, released its second quarter results on August 14, 2025. The

MacroGenics (NASDAQ:MGNX), a biotechnology company focused on antibody-based cancer treatments, reported its second-quarter results on August 14, 2025. The release showed GAAP revenue of $22.2

SurgePays (NASDAQ:SURG) reported its fiscal Q2 2025 earnings on August 5, 2025 (for the quarter ended June 30, 2025), with revenue rose 8.9% quarter over quarter to $11.5 million and issued revenue

Codexis (NASDAQ:CDXS), a biotechnology company specializing in enzyme engineering for pharmaceutical manufacturing, released its second quarter 2025 results on August 13, 2025. The headline news was

Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a

XOMA (NASDAQ:XOMA), a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company’s revenue (GAAP) reached $13.1 million for Q2

Adaptimmune Therapeutics Plc (NASDAQ:ADAP), a biotechnology company specializing in engineered T-cell therapies for cancer, released its second-quarter earnings on August 13, 2025, covering results